CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate ...
The principal investigator of the trial, Ellis is a radiation oncologist and physician-scientist at the Tampa General Cancer Institute, Tampa General Hospital and serves as direct ...
The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of ...
News-Medical.Net on MSN
Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...
"What a life I've had.....I was very privileged, I saw the world, I witnessed history in the making and I did things people ...
Accuray Incorporated ( NASDAQ: ARAY) Shareholder/Analyst Call September 29, 2025 4:30 PM EDT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback